Abata Therapeutics

Abata Therapeutics

Edit info

  • Founded: 2021
  • Location: Cambridge, MA
  • Employee range: 11 - 50
  • Clinical stage: Clin0
  • Therapy area: MS
  • Drug types: IMM, NEU, END, MUS
  • Lead product: ABA-101
  • Funding: $95M A Jun 2021


abatatx.com

linkedin.com

job board


Business:

Treg Cell Therapies

Drug notes:

Undisclosed programs RD diabetes (1), RD inclusion body myositis

About:

Abata Therapeutics is understanding the biology of T cells to create therapies for autoimmune diseases. Regulatory T cells (Tregs) are a critical component of the immune system that act to suppress the immune response preventing autoimmunity. Abata is using this knowledge to engineer Tregs as targeted therapies that stop immune-mediated destruction of normal cells and restore homeostasis. Treg engineering involves expression of a T cell receptor that recognizes a tissue-restricted antigen, to selectively target the therapy to the site of disease for a robust response. In addition, engineered Tregs are optimized for durability allowing the effects of a single dose to last years. Abata has initial programs for multiple sclerosis and Type 1 diabetes.

Jobs:

Post a job

News:

Abata Therapeutics to Present at Upcoming Investor and Industry Events in June
crunchbase
May 31, 2023
Science/business updates
external-link
A Life in Biotech & the Cell Therapy Wave: David Hallal on The Long Run - Timmerman Report
googlenews
Feb 28, 2023
Science/business updates
external-link
Journal of Experimental Medicine, 2004
web
Dec 23, 2024
Science/business updates
external-link
9 Story Building at Arsenal Yards Fully Leased, 5 Life Science Tenants Coming 100 Forge - Watertown News
googlenews
Dec 9, 2021
Science/business updates
external-link
Journal of Autoimmunity, August 2018
web
Dec 23, 2024
Science/business updates
external-link
1st Abata Candidate Will Be T-cell Therapy ABA-101 for Progressive MS - Multiple Sclerosis News Today
googlenews
Dec 15, 2022
Science/business updates
external-link
Abata Therapeutics Launches to Usher in New Era of Cell Therapy Using Targeted Regulatory T Cells to Treat Serious Autoimmune and Inflammatory Diseases - Business Wire
googlenews
Jun 23, 2021
Science/business updates
external-link
JCI Insight, 2022:
web
Dec 23, 2024
Science/business updates
external-link
Our new CTO, Joanne Tzouvalopoulos Beck’s take on joining Abata and her excitement surrounding our groundbreaking partnership with ElevateBio to support clinical advancement and pipeline expansion. L
linkedin
Sep 19, 2024
New hires
external-link
Mar 2023 Opinion & Video: A new MRI technique gives insight into mechanisms underlaying MS progr
web
Dec 20, 2024
Science/business updates
external-link
Preclinical Development of a T Cell Receptor Engineered Regulatory T Cell (Treg) Therapy for Progressive Pathology in MS ACTRIMS 2024 Poster February 29, 2024
web
Dec 19, 2024
Science/business updates
external-link
New investment to advance Abata’s T-cell therapy for progressive MS - Multiple Sclerosis News Today
googlenews
Aug 22, 2024
Funding-related
external-link
Sept 2010 Demonstration of Treg stability in vivo in the presence of inflammatory autoimmune con
web
Dec 19, 2024
Science/business updates
external-link
Third Rock-backed startup launches to develop cell therapies for MS, diabetes - BioPharma Dive
googlenews
Jun 23, 2021
Science/business updates
external-link
In Vivo Nonclinical Evaluation of Activity and Safety of a T Cell Receptor Engineered Regulatory T Cell Therapy for MS Progression Independent of Relapse Activity ECTRIMS 2024
web
Dec 19, 2024
Science/business updates
external-link
Cell therapy weekly: US FDA grants Orphan Drug Designation to a gene therapy for a type of retinal disease - RegMedNet
googlenews
Sep 5, 2024
Science/business updates
external-link
In this article with the National MS Society, our CEO Samantha Singer shares her deeply personal journey with multiple sclerosis. Her story is a testament to the life-changing impact of treatments th
linkedin
Dec 17, 2024
New hires
external-link
In September, we added three amazing new employees, including Joanne Tzouvalopoulos Beck, our new CTO, Loundja BENSEGHIR, our AD of Quality Assurance and Surbhi Kansagara, Sr. Research Assoc. We are t
linkedin
Oct 19, 2024
New hires
external-link
Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement of its Treg Cell Therapy Pipeline into Clinical Development - GlobeNewswire
googlenews
Aug 15, 2024
Funding-related
external-link
Abata Therapeutics Appoints David Kaufman, M.D., Ph.D., to its Board of Directors
crunchbase
Mar 9, 2023
New hires
external-link
Feb 2022 Demonstration that meningeal inflammation is associated with chronic-active white matte
web
Dec 19, 2024
Science/business updates
external-link
2004 Demonstration that antigen-specific Tregs are much more effective than polyclonal Tregs in
web
Dec 19, 2024
Science/business updates
external-link
Functional Characterization of Regulatory T cell (Treg) Therapy for the Treatment of Type 1 Diabetes (T1D) nPOD 2024 Poster February 19, 2024
web
Dec 19, 2024
Science/business updates
external-link
Abata Therapeutics announces equity investment from Bristol Myers
crunchbase
Aug 15, 2024
Funding-related
external-link
Fun-filled time at the Ragnar Sprint Reach the Beach race where our amazing team of Abatars hit the ground running for the third year in a row.  Our 3-person ultra-team placed first in the ultra-spr
linkedin
Oct 19, 2024
Science/business updates
external-link
Mar 2024 Harnessing regulatory T cells to establish immune tolerance
web
Dec 19, 2024
Science/business updates
external-link
At this time of year, we reflect on one of our core values – "Strengthened by Differences" – as we come together to celebrate Diversity Awareness Month and the upcoming holiday season. Our annual potl
linkedin
Nov 19, 2024
New hires
external-link
a first-in-human clinical trial
web
Dec 23, 2024
Science/business updates
external-link
BioTechnology Innovators Honored in 3rd Annual BioTech ...
crunchbase
Nov 22, 2023
Science/business updates
external-link
Last month we added an incredible new Principal Scientist to the team - Stephanie Morgan! We’re excited to have Stephanie on board as we look forward to a momentum-filled end of 2024 and beyond! Welco
linkedin
Nov 19, 2024
New hires
external-link
Venture Report: Halda bringing RIPTACs into clinic with crossover round - BioCentury
googlenews
Aug 15, 2024
Funding-related
external-link
Sept 2012 Review: T cells circulate through the cerebrospinal fluid in the meningeal compartment
web
Dec 19, 2024
Science/business updates
external-link
Cell, September 2018
web
Dec 23, 2024
Science/business updates
external-link
Nature Immunology, 2003
web
Dec 23, 2024
Science/business updates
external-link
New England Journal of Medicine, 2007
web
Dec 23, 2024
Science/business updates
external-link
75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight
crunchbase
Nov 13, 2024
Science/business updates
external-link
Science, 2003
web
Dec 23, 2024
Science/business updates
external-link
Unveiling Novel T-cell Receptors (TCRs) for Enhanced Treg Cell Therapy in Type 1 Diabetes (T1D) nPOD 2024 Poster February 19, 2024
web
Dec 19, 2024
Science/business updates
external-link
Abata Therapeutics to Present and Participate in Upcoming Investor and Industry Events Press Release August 28, 2023
web
Dec 19, 2024
Science/business updates
external-link
New CEOs at Nura, IMU - BioCentury
googlenews
Sep 18, 2024
New hires
external-link
Immunity, February 2012
web
Dec 23, 2024
Science/business updates
external-link
Read Press Release
web
Dec 20, 2024
Science/business updates
external-link
Science, 2019
web
Dec 23, 2024
Science/business updates
external-link
Abata hopes to find 'perfect fit' with MS cell therapy after ...
fiercebiotech.com
Dec 19, 2024
Science/business updates
external-link
2003 Demonstration that FoxP3 functions as a key driver of Treg development and phenotype.
web
Dec 19, 2024
Science/business updates
external-link
Abata Therapeutics Appoints Joanne Beck, Ph.D., as Chief Technical Officer
crunchbase
Sep 16, 2024
New hires
external-link
Abata Therapeutics Receives FDA Fast Track Designation for - GlobeNewswire
googlenews
Aug 22, 2024
Science/business updates
external-link
Top 10 US Biopharma Series A Rounds of 2021 – So Far! - BioSpace
googlenews
Sep 24, 2021
Funding-related
external-link
Sep 2021 Reinforcement of the therapeutic strategy to target the adaptive immune system to treat
web
Dec 19, 2024
Science/business updates
external-link
Abata Therapeutics selects ABA-201 Treg cell therapy as development candidate for type 1 diabetes - BioWorld Online
googlenews
Aug 24, 2023
Science/business updates
external-link
1Journal of Immunology, October 1981
web
Dec 23, 2024
Science/business updates
external-link
Sept 2018 Demonstration that peripheral blood CD4+ T cells of MS patients can be analyzed to ide
web
Dec 19, 2024
Science/business updates
external-link
View Our Newsroom
web
Dec 23, 2024
Science/business updates
external-link
Disrupters: Samantha Singer - PharmaVoice
googlenews
Sep 6, 2022
New hires
external-link
Abata Therapeutics' Treg Therapy ABA-101 Garners FDA Fast Track Designation - CGTLive™
googlenews
Sep 1, 2024
Science/business updates
external-link
It was great speaking with ElevateBio about our ongoing manufacturing partnership, which expedited our lead program, ABA-101 for the treatment of progressive multiple sclerosis, and set up a template
linkedin
Dec 19, 2024
Science/business updates
external-link
People - Nature.com
googlenews
Nov 12, 2024
New hires
external-link
Science Translational Medicine, November 2015
web
Dec 23, 2024
Science/business updates
external-link
JCI Insight, 2023
web
Dec 23, 2024
Science/business updates
external-link
Phase 1 trial of ABA-101 in progressive MS expected by year's end - Multiple Sclerosis News Today
googlenews
Jul 12, 2024
Science/business updates
external-link
Aug 1995 First identification of a suppressive T cell population – renamed regulatory T cells or
web
Dec 19, 2024
Science/business updates
external-link
Abata Therapeutics Announces Second Development Candidate, ABA-201, a Novel Treg Cell Therapy for the Treatment of Type 1 Diabetes - Business Wire
googlenews
Aug 24, 2023
Science/business updates
external-link
Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement of its Treg Cell Therapy Pipeline into Clinical Development Press Release
web
Dec 19, 2024
Funding-related
external-link
Abata gets equity investment from Bristol Myers Squibb - BioWorld Online
googlenews
Aug 16, 2024
Funding-related
external-link
Nov 2015 Demonstration that autologous human Tregs can be vastly expanded ex vivo, safely transf
web
Dec 19, 2024
Science/business updates
external-link
Abata Therapeutics Announces FDA Clearance of Investigational New Drug Application for Clinical Evaluation of ABA-101 in Progressive Multiple Sclerosis
crunchbase
Jul 11, 2024
Science/business updates
external-link
How venture philanthropy is changing the game in drug development - The Business Journals
googlenews
Jan 26, 2024
Science/business updates
external-link
Third Rock-Seeded Abata Aims Tregs, $95 Million at Autoimmune Diseases - BioSpace
googlenews
Jun 23, 2021
Funding-related
external-link
June 2021 Abata Therapeutics Launches to Usher in New Era of Cell Therapy Using Targeted Regulat
web
Dec 19, 2024
Science/business updates
external-link
2007-2019 A series of genetic analyses demonstrated that the inherited susceptibility to MS was
web
Dec 19, 2024
Science/business updates
external-link
Abata Therapeutics Appoints Joanne Beck, Ph.D., as Chief Technical Officer - GlobeNewswire
googlenews
Sep 16, 2024
New hires
external-link
Abata obtains IND clearance for autologous TCR-Treg therapy for progressive MS
crunchbase
Jul 11, 2024
Science/business updates
external-link
Stable regulatory t cells and methods of production
crunchbase
Aug 10, 2023
Science/business updates
external-link
What’s Tipping the Scale for Bioprocessing? - Genetic Engineering & Biotechnology News
googlenews
Sep 3, 2024
Science/business updates
external-link
AstraZeneca pays $85M to Quell Type 1 diabetes with 'one and done' cell therapy - Fierce Biotech
googlenews
Jun 9, 2023
Funding-related
external-link
This weekend, the Abata team took part in the Breakthrough T1D Walk in Boston. We are proud to join forces with the type 1 diabetes community to elevate awareness and champion research for T1D. By co
linkedin
Oct 19, 2024
Science/business updates
external-link
Abata Therapeutics Strengthens Board of Directors
crunchbase
Jul 28, 2021
New hires
external-link
Abata hopes to find ‘perfect fit’ with MS cell therapy after $95M series A - Fierce Biotech
googlenews
Jun 23, 2021
Funding-related
external-link
How Abata new strategy in non-relapsing MS? Third Rock leads $95M series A
crunchbase
Jun 23, 2021
Funding-related
external-link
Frontiers in Immunology, Jan 2019
web
Dec 23, 2024
Science/business updates
external-link
Nature, September 2021
web
Dec 23, 2024
Science/business updates
external-link
JAMA Neurology, August 2019
web
Dec 23, 2024
Science/business updates
external-link
Journal of Autoimmunity, January 2020
web
Dec 23, 2024
Science/business updates
external-link
Abata Therapeutics Appoints Joanne Beck, Ph.D., as Chief Technical Officer Press Release September 16, 2024
web
Dec 19, 2024
New hires
external-link
Journal of Immunology, August 1995
web
Dec 23, 2024
Science/business updates
external-link
Abata Therapeutics Announces FDA Clearance of Investigational New Drug Application for Clinical Evaluation of ABA-101 in Progressive Multiple Sclerosis Press Release
web
Dec 19, 2024
Science/business updates
external-link
Feb 2012 First demonstration that stable Tregs originate from the thymus before entering the blo
web
Dec 19, 2024
Science/business updates
external-link
Nature Reviews: Immunology, Sept. 2012
web
Dec 23, 2024
Science/business updates
external-link
Aug 2018 Demonstration of heterologous/infectious tolerance in mouse EAE models of CNS inflammat
web
Dec 19, 2024
Science/business updates
external-link
For the second year running, Samantha Singer, CEO, will be a panelist at #WMIF2024. This year, she’s participating in a panel discussion on the role of cell therapies for autoimmune diseases. We’re lo
linkedin
Oct 19, 2024
Science/business updates
external-link
Jan 2020 Demonstration that Tregs can be used to treat autoimmune disease in mice, when engineer
web
Dec 19, 2024
Science/business updates
external-link
Science, September 2010
web
Dec 23, 2024
Science/business updates
external-link
Are Cellular Therapies the Future of Autoimmune Disease? Medscape October 23, 2023
web
Dec 19, 2024
Science/business updates
external-link
Nature, 2011
web
Dec 23, 2024
Science/business updates
external-link
Harnessing regulatory T cells to establish immune tolerence Science Translational Medicine March 13, 2024
web
Dec 20, 2024
Science/business updates
external-link
Today, our CSO Ellen Cahir-McFarland presented in vivo preclinical data on our lead program, ABA-101, indicating that our TCR-engineered Tregs are doing what they were designed to do. The data support
linkedin
Sep 19, 2024
Science/business updates
external-link
Jan 2019 Review: Targeting autoreactive T cells with Tregs is a valid therapeutic approach in MS
web
Dec 19, 2024
Science/business updates
external-link
Aug 2019 First demonstration that chronic-active demyelinating lesions, a biomarker of ongoing i
web
Dec 19, 2024
Science/business updates
external-link
Abata Therapeutics Announces FDA Clearance of Investigational New Drug Application for Clinical Evaluation of ABA-101 in Progressive Multiple Sclerosis - Yahoo Finance
googlenews
Jul 9, 2024
Science/business updates
external-link
Cell therapies for multiple sclerosis
crunchbase
Aug 10, 2023
Science/business updates
external-link


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com